Free Trial
NASDAQ:INZY

Inozyme Pharma Q4 2023 Earnings Report

Inozyme Pharma logo
$4.00 0.00 (0.00%)
As of 07/1/2025

Inozyme Pharma EPS Results

Actual EPS
-$0.35
Consensus EPS
-$0.31
Beat/Miss
Missed by -$0.04
One Year Ago EPS
N/A

Inozyme Pharma Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Inozyme Pharma Announcement Details

Quarter
Q4 2023
Time
N/A
Conference Call Date
Tuesday, March 12, 2024
Conference Call Time
8:00AM ET

Upcoming Earnings

Inozyme Pharma's Q2 2025 earnings is scheduled for Tuesday, August 5, 2025, with a conference call scheduled on Wednesday, August 6, 2025 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Inozyme Pharma Earnings Headlines

Inozyme Pharma Inc News (INZY) - Investing.com
Market Panic: Trump Just Dropped a Bomb on Your Stocks
tock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tariffs just lit the fuse. Millions of investors are blindsided as stocks plunge… but this is only Phase 1. If you're still holding the wrong assets, you could lose 30% or more in the coming weeks.
Inozyme Pharma Inc Ordinary Shares
See More Inozyme Pharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Inozyme Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Inozyme Pharma and other key companies, straight to your email.

About Inozyme Pharma

Inozyme Pharma (NASDAQ:INZY) is a clinical‐stage biotechnology company dedicated to developing therapies for patients suffering from rare, inherited disorders characterized by ectopic calcification. The firm’s research focuses on identifying and restoring key enzyme functions that regulate mineral metabolism and tissue mineralization. Central to Inozyme’s mission is the development of novel recombinant enzymes designed to correct underlying biochemical defects and prevent the life‐threatening complications associated with abnormal calcium deposition in soft tissues and vasculature.

Inozyme’s lead candidate, INZ‐701, is a recombinant alkaline phosphatase designed to treat pseudoxanthoma elasticum (PXE), a genetic condition that causes progressive calcification of elastic fibers in the skin, eyes and cardiovascular system. Preclinical studies of INZ‐701 have demonstrated effective modulation of pyrophosphate metabolism, a key inhibitor of tissue mineralization, with early clinical trials underway to evaluate safety and pharmacodynamic effects. The company’s preclinical pipeline also includes INZ‐801, targeting autosomal recessive hypophosphatemic rickets type 1 (ARHR1), and exploratory programs in other calcification disorders.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Inozyme emerged from partnerships with leading academic institutions and venture capital firms. The company is led by Chief Executive Officer Jeffrey Latham, Ph.D., a biopharmaceutical veteran with extensive experience in rare disease research and development. Inozyme’s leadership team brings expertise from pioneering roles at companies such as Alexion, Shire and Novartis, while its scientific advisory board comprises clinicians and researchers specializing in metabolic bone disease and vascular biology.

Inozyme Pharma maintains active engagement with global regulatory agencies to secure orphan drug designations and fast‐track pathways. The company collaborates with patient advocacy groups in North America and Europe to support community education and streamline clinical trial enrollment. Through its targeted enzyme replacement approach, Inozyme aims to address significant unmet medical needs and improve quality of life for patients living with debilitating calcification disorders.

View Inozyme Pharma Profile

More Earnings Resources from MarketBeat